Scientists at USC have discovered a new type of drug for the treatment of ovarian cancer that works in a way that should not only decrease the number of doses that patients need to take, but also may make it effective for patients whose cancer has become drug-resistant. The drug, which so far has been tested in the lab on ovarian cancer cells and on mice tumors, was unveiled last month in the Proceedings of the National Academy of Sciences (PNAS).
Eating an apple a day might in fact help keeps the cardiologist away, new research suggests. In a study of healthy, middle-aged adults, consumption of one apple a day for four weeks lowered by 40 percent blood levels of a substance linked to hardening of the arteries. Taking capsules containing polyphenols, a type of antioxidant found in apples had a similar, but not as large, effect.
An older medication originally approved to treat heart problems eases pain and stiffness from a very rare muscle disease, a new study reports. The findings are good news not only for the relatively small number of people around the world estimated to have the disease—nondystrophic myotonia—but also for many other patients who have one of the thousands of other diseases that are very rare, neurologists say.
Celegen Corporation's Revlimid Combo Fails as Prostate Cancer Therapy Adding lenalidomide (Revlimid) to the chemotherapy regimen led to greater toxicity and worse survival in patients with untreated castration-resistant prostate cancer (CRPC), results of a large international trial showed. Men randomized to a regimen of lenalidomide, docetaxel, and prednisone, had a 53% increased mortality hazard, a 32% greater hazard for progression, and significantly higher rates of neutropenia, febrile neutropenia, and multiple non-hematologic adverse events.
Governor Dannel P. Malloy today announced the state will provide up to $2.25 million in grants to Durata Therapeutics, Inc. to support the relocation of its research and development, clinical, and regulatory operations from New Jersey to Branford. The company, whose headquarters are in Chicago, Illinois, will create up to 80 new, full-time jobs in Connecticut. “The goal of Bioscience Connecticut is twofold – creating good paying jobs with good benefits for residents in an industry that is poised for growth,” said Governor Malloy.